Table 2 Details and Outcomes of the patients treated with anti-TNF alpha antibodies
Case# | Anti-TNF alpha | Duration of anti-TNF* alpha therapy | Combined azathoprine | Side effects | Response to anti-TNF alpha therapy |
|---|---|---|---|---|---|
1 | Infliximab | 1 year (discontinued) | Yes | No | Remission |
2 | Adalibmab | More than 1 year (discontinued) | Yes | No | Partial response |
3 | Infliximab | Several weeks (continued) | Yes | No | Remission |
4 | Infliximab | 4 weeks (discontinued) | No | No | Remission |